Eintrag weiter verarbeiten
Use of deferasirox (Exjade) for iron overload in peritoneal dialysis patients
Gespeichert in:
| Zeitschriftentitel: | Nephrology |
|---|---|
| Personen und Körperschaften: | , , , |
| In: | Nephrology, 23, 2018, 9, S. 887-889 |
| Format: | E-Article |
| Sprache: | Englisch |
| veröffentlicht: |
Wiley
|
| Schlagwörter: |
| author_facet |
Yii, Erwin Doery, James CG Kaplan, Zane Kerr, Peter G Yii, Erwin Doery, James CG Kaplan, Zane Kerr, Peter G |
|---|---|
| author |
Yii, Erwin Doery, James CG Kaplan, Zane Kerr, Peter G |
| spellingShingle |
Yii, Erwin Doery, James CG Kaplan, Zane Kerr, Peter G Nephrology Use of deferasirox (Exjade) for iron overload in peritoneal dialysis patients Nephrology General Medicine |
| author_sort |
yii, erwin |
| spelling |
Yii, Erwin Doery, James CG Kaplan, Zane Kerr, Peter G 1320-5358 1440-1797 Wiley Nephrology General Medicine http://dx.doi.org/10.1111/nep.13389 <jats:title>ABSTRACT</jats:title><jats:p>A 54 year old male with b‐Thalassemia major developed ESRD and was managed with continuous ambulatory peritoneal dialysis. Although not able to be transfused due to high titre red cell antibodies he did require management of iron overload. Deferasirox (Exjade) was administered orally. There was concern that excretion of iron via the peritoneal dialysate may raise the risk of iron‐dependent infections (Yersinia and Rhizopus).Whilst receiving Exjade 1000mg /day, a total collection of 12.7L of peritoneal dialysate was collected over a 24 hour period by the patient. The dialysate total iron levels were measured by ICP‐MS at 0.46mmol/L which equates to 0.33mg of Fe in total. Over a 6 month period his serum ferritin fell from 3869μg/l to 1545μg/l. There were no episodes of peritonitis. Since only 7‐8% of the deferasirox and iron complex is excreted through the urine, the amount of Fe seen in the patient's dialysate might be expected to be up to 1.5‐1.6mg. Yet, the results of the Fe levels in the patient’s PD fluid was a meagre 0.33mg, about five times lower than expected.Whilst only moderately effective at a dosage of 1000mg/day, deferasirox may be a safe agent for iron removal in iron overloaded peritoneal dialysis patients, as relatively low dialysate iron levels reduces the risk of Yersinia and Rhizopus infection.</jats:p> Use of deferasirox (Exjade) for iron overload in peritoneal dialysis patients Nephrology |
| doi_str_mv |
10.1111/nep.13389 |
| facet_avail |
Online |
| finc_class_facet |
Medizin |
| format |
ElectronicArticle |
| fullrecord |
blob:ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTExMS9uZXAuMTMzODk |
| id |
ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTExMS9uZXAuMTMzODk |
| institution |
DE-Gla1 DE-Zi4 DE-15 DE-Pl11 DE-Rs1 DE-105 DE-14 DE-Ch1 DE-L229 DE-D275 DE-Bn3 DE-Brt1 DE-D161 |
| imprint |
Wiley, 2018 |
| imprint_str_mv |
Wiley, 2018 |
| issn |
1320-5358 1440-1797 |
| issn_str_mv |
1320-5358 1440-1797 |
| language |
English |
| mega_collection |
Wiley (CrossRef) |
| match_str |
yii2018useofdeferasiroxexjadeforironoverloadinperitonealdialysispatients |
| publishDateSort |
2018 |
| publisher |
Wiley |
| recordtype |
ai |
| record_format |
ai |
| series |
Nephrology |
| source_id |
49 |
| title |
Use of deferasirox (Exjade) for iron overload in peritoneal dialysis patients |
| title_unstemmed |
Use of deferasirox (Exjade) for iron overload in peritoneal dialysis patients |
| title_full |
Use of deferasirox (Exjade) for iron overload in peritoneal dialysis patients |
| title_fullStr |
Use of deferasirox (Exjade) for iron overload in peritoneal dialysis patients |
| title_full_unstemmed |
Use of deferasirox (Exjade) for iron overload in peritoneal dialysis patients |
| title_short |
Use of deferasirox (Exjade) for iron overload in peritoneal dialysis patients |
| title_sort |
use of deferasirox (exjade) for iron overload in peritoneal dialysis patients |
| topic |
Nephrology General Medicine |
| url |
http://dx.doi.org/10.1111/nep.13389 |
| publishDate |
2018 |
| physical |
887-889 |
| description |
<jats:title>ABSTRACT</jats:title><jats:p>A 54 year old male with b‐Thalassemia major developed ESRD and was managed with continuous ambulatory peritoneal dialysis. Although not able to be transfused due to high titre red cell antibodies he did require management of iron overload. Deferasirox (Exjade) was administered orally. There was concern that excretion of iron via the peritoneal dialysate may raise the risk of iron‐dependent infections (Yersinia and Rhizopus).Whilst receiving Exjade 1000mg /day, a total collection of 12.7L of peritoneal dialysate was collected over a 24 hour period by the patient. The dialysate total iron levels were measured by ICP‐MS at 0.46mmol/L which equates to 0.33mg of Fe in total. Over a 6 month period his serum ferritin fell from 3869μg/l to 1545μg/l. There were no episodes of peritonitis. Since only 7‐8% of the deferasirox and iron complex is excreted through the urine, the amount of Fe seen in the patient's dialysate might be expected to be up to 1.5‐1.6mg. Yet, the results of the Fe levels in the patient’s PD fluid was a meagre 0.33mg, about five times lower than expected.Whilst only moderately effective at a dosage of 1000mg/day, deferasirox may be a safe agent for iron removal in iron overloaded peritoneal dialysis patients, as relatively low dialysate iron levels reduces the risk of Yersinia and Rhizopus infection.</jats:p> |
| container_issue |
9 |
| container_start_page |
887 |
| container_title |
Nephrology |
| container_volume |
23 |
| format_de105 |
Article, E-Article |
| format_de14 |
Article, E-Article |
| format_de15 |
Article, E-Article |
| format_de520 |
Article, E-Article |
| format_de540 |
Article, E-Article |
| format_dech1 |
Article, E-Article |
| format_ded117 |
Article, E-Article |
| format_degla1 |
E-Article |
| format_del152 |
Buch |
| format_del189 |
Article, E-Article |
| format_dezi4 |
Article |
| format_dezwi2 |
Article, E-Article |
| format_finc |
Article, E-Article |
| format_nrw |
Article, E-Article |
| _version_ |
1792339735917625354 |
| geogr_code |
not assigned |
| last_indexed |
2024-03-01T15:52:33.933Z |
| geogr_code_person |
not assigned |
| openURL |
url_ver=Z39.88-2004&ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fvufind.svn.sourceforge.net%3Agenerator&rft.title=Use+of+deferasirox+%28Exjade%29+for+iron+overload+in+peritoneal+dialysis+patients&rft.date=2018-09-01&genre=article&issn=1440-1797&volume=23&issue=9&spage=887&epage=889&pages=887-889&jtitle=Nephrology&atitle=Use+of+deferasirox+%28Exjade%29+for+iron+overload+in+peritoneal+dialysis+patients&aulast=Kerr&aufirst=Peter+G&rft_id=info%3Adoi%2F10.1111%2Fnep.13389&rft.language%5B0%5D=eng |
| SOLR | |
| _version_ | 1792339735917625354 |
| author | Yii, Erwin, Doery, James CG, Kaplan, Zane, Kerr, Peter G |
| author_facet | Yii, Erwin, Doery, James CG, Kaplan, Zane, Kerr, Peter G, Yii, Erwin, Doery, James CG, Kaplan, Zane, Kerr, Peter G |
| author_sort | yii, erwin |
| container_issue | 9 |
| container_start_page | 887 |
| container_title | Nephrology |
| container_volume | 23 |
| description | <jats:title>ABSTRACT</jats:title><jats:p>A 54 year old male with b‐Thalassemia major developed ESRD and was managed with continuous ambulatory peritoneal dialysis. Although not able to be transfused due to high titre red cell antibodies he did require management of iron overload. Deferasirox (Exjade) was administered orally. There was concern that excretion of iron via the peritoneal dialysate may raise the risk of iron‐dependent infections (Yersinia and Rhizopus).Whilst receiving Exjade 1000mg /day, a total collection of 12.7L of peritoneal dialysate was collected over a 24 hour period by the patient. The dialysate total iron levels were measured by ICP‐MS at 0.46mmol/L which equates to 0.33mg of Fe in total. Over a 6 month period his serum ferritin fell from 3869μg/l to 1545μg/l. There were no episodes of peritonitis. Since only 7‐8% of the deferasirox and iron complex is excreted through the urine, the amount of Fe seen in the patient's dialysate might be expected to be up to 1.5‐1.6mg. Yet, the results of the Fe levels in the patient’s PD fluid was a meagre 0.33mg, about five times lower than expected.Whilst only moderately effective at a dosage of 1000mg/day, deferasirox may be a safe agent for iron removal in iron overloaded peritoneal dialysis patients, as relatively low dialysate iron levels reduces the risk of Yersinia and Rhizopus infection.</jats:p> |
| doi_str_mv | 10.1111/nep.13389 |
| facet_avail | Online |
| finc_class_facet | Medizin |
| format | ElectronicArticle |
| format_de105 | Article, E-Article |
| format_de14 | Article, E-Article |
| format_de15 | Article, E-Article |
| format_de520 | Article, E-Article |
| format_de540 | Article, E-Article |
| format_dech1 | Article, E-Article |
| format_ded117 | Article, E-Article |
| format_degla1 | E-Article |
| format_del152 | Buch |
| format_del189 | Article, E-Article |
| format_dezi4 | Article |
| format_dezwi2 | Article, E-Article |
| format_finc | Article, E-Article |
| format_nrw | Article, E-Article |
| geogr_code | not assigned |
| geogr_code_person | not assigned |
| id | ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTExMS9uZXAuMTMzODk |
| imprint | Wiley, 2018 |
| imprint_str_mv | Wiley, 2018 |
| institution | DE-Gla1, DE-Zi4, DE-15, DE-Pl11, DE-Rs1, DE-105, DE-14, DE-Ch1, DE-L229, DE-D275, DE-Bn3, DE-Brt1, DE-D161 |
| issn | 1320-5358, 1440-1797 |
| issn_str_mv | 1320-5358, 1440-1797 |
| language | English |
| last_indexed | 2024-03-01T15:52:33.933Z |
| match_str | yii2018useofdeferasiroxexjadeforironoverloadinperitonealdialysispatients |
| mega_collection | Wiley (CrossRef) |
| physical | 887-889 |
| publishDate | 2018 |
| publishDateSort | 2018 |
| publisher | Wiley |
| record_format | ai |
| recordtype | ai |
| series | Nephrology |
| source_id | 49 |
| spelling | Yii, Erwin Doery, James CG Kaplan, Zane Kerr, Peter G 1320-5358 1440-1797 Wiley Nephrology General Medicine http://dx.doi.org/10.1111/nep.13389 <jats:title>ABSTRACT</jats:title><jats:p>A 54 year old male with b‐Thalassemia major developed ESRD and was managed with continuous ambulatory peritoneal dialysis. Although not able to be transfused due to high titre red cell antibodies he did require management of iron overload. Deferasirox (Exjade) was administered orally. There was concern that excretion of iron via the peritoneal dialysate may raise the risk of iron‐dependent infections (Yersinia and Rhizopus).Whilst receiving Exjade 1000mg /day, a total collection of 12.7L of peritoneal dialysate was collected over a 24 hour period by the patient. The dialysate total iron levels were measured by ICP‐MS at 0.46mmol/L which equates to 0.33mg of Fe in total. Over a 6 month period his serum ferritin fell from 3869μg/l to 1545μg/l. There were no episodes of peritonitis. Since only 7‐8% of the deferasirox and iron complex is excreted through the urine, the amount of Fe seen in the patient's dialysate might be expected to be up to 1.5‐1.6mg. Yet, the results of the Fe levels in the patient’s PD fluid was a meagre 0.33mg, about five times lower than expected.Whilst only moderately effective at a dosage of 1000mg/day, deferasirox may be a safe agent for iron removal in iron overloaded peritoneal dialysis patients, as relatively low dialysate iron levels reduces the risk of Yersinia and Rhizopus infection.</jats:p> Use of deferasirox (Exjade) for iron overload in peritoneal dialysis patients Nephrology |
| spellingShingle | Yii, Erwin, Doery, James CG, Kaplan, Zane, Kerr, Peter G, Nephrology, Use of deferasirox (Exjade) for iron overload in peritoneal dialysis patients, Nephrology, General Medicine |
| title | Use of deferasirox (Exjade) for iron overload in peritoneal dialysis patients |
| title_full | Use of deferasirox (Exjade) for iron overload in peritoneal dialysis patients |
| title_fullStr | Use of deferasirox (Exjade) for iron overload in peritoneal dialysis patients |
| title_full_unstemmed | Use of deferasirox (Exjade) for iron overload in peritoneal dialysis patients |
| title_short | Use of deferasirox (Exjade) for iron overload in peritoneal dialysis patients |
| title_sort | use of deferasirox (exjade) for iron overload in peritoneal dialysis patients |
| title_unstemmed | Use of deferasirox (Exjade) for iron overload in peritoneal dialysis patients |
| topic | Nephrology, General Medicine |
| url | http://dx.doi.org/10.1111/nep.13389 |